1. Home
  2. ADAM vs ABUS Comparison

ADAM vs ABUS Comparison

Compare ADAM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADAM

Adamas Trust Inc.

HOLD

Current Price

$9.31

Market Cap

826.7M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.28

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAM
ABUS
Founded
2003
2005
Country
United States
United States
Employees
221
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.7M
839.5M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
ADAM
ABUS
Price
$9.31
$4.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$9.17
$5.00
AVG Volume (30 Days)
531.0K
1.4M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
11.87%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.08
$239.71
P/E Ratio
$41.51
$4.93
Revenue Growth
N/A
128.21
52 Week Low
$6.45
$3.04
52 Week High
$9.32
$5.10

Technical Indicators

Market Signals
Indicator
ADAM
ABUS
Relative Strength Index (RSI) 62.24 47.21
Support Level $7.72 $4.16
Resistance Level N/A $4.60
Average True Range (ATR) 0.19 0.18
MACD -0.01 -0.02
Stochastic Oscillator 76.43 30.14

Price Performance

Historical Comparison
ADAM
ABUS

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: